Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Taysha Gene Therapies Inc (NQ: TSHA ) 2.070 -0.080 (-3.72%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Taysha Gene Therapies Inc < Previous 1 2 3 4 5 6 7 8 9 Next > The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year December 26, 2021 Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating... Via Benzinga Taysha Gene Therapies Added to the ICE Biotechnology Index December 23, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design December 22, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Analyst Ratings For Taysha Gene Therapies August 18, 2021 Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst rat... Via Benzinga The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline August 18, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... Via Benzinga Exposures Product Safety Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease December 16, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies Added to the Nasdaq Biotechnology Index December 15, 2021 From Taysha Gene Therapies Via Business Wire The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré December 07, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021 December 16, 2021 Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE: Via Benzinga Taysha Gene's Epilepsy Candidate Shows Encouraging Action In Preclinical Studies December 07, 2021 Taysha Gene Therapies Inc (NASDAQ: TSHA) announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy.... Via Benzinga Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency December 06, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies, Inc. (TSHA) Q3 2021 Earnings Call Transcript November 11, 2021 TSHA earnings call for the period ending September 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update November 10, 2021 From Taysha Gene Therapies Via Business Wire Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences November 08, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10 November 03, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement Approach Demonstrating Therapeutic Potential for The Treatment of Angelman Syndrome in the Journal JCI Insight October 25, 2021 From Taysha Gene Therapies Via Business Wire Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit October 21, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence October 13, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome October 12, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a Grant Award to Batten Hope October 05, 2021 From Taysha Gene Therapies Via Business Wire Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis September 29, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies to Participate in Upcoming October Investor Healthcare Conferences September 28, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome September 22, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies Announces Publication of Positive Preclinical Data for TSHA-104 Demonstrating Therapeutic Potential in SURF1-associated Leigh Syndrome in Journal Molecular Therapy: Methods & Clinical Development September 15, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome September 08, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha Gene Therapies to Participate in Upcoming September Investor Healthcare Conferences September 01, 2021 From Taysha Gene Therapies, Inc. Via Business Wire Taysha's Rare Epilepsy Gene Therapy Receives European Orphan Drug Tag August 25, 2021 The European Commission has granted Orphan Drug designation to Taysha Gene Therapies Inc's (NASDAQ: TSHA) TSHA-105, AAV9-based gene therapy for SLC13A5-... Via Benzinga Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency From the European Commission August 25, 2021 From Taysha Gene Therapies, Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's Intraday Session August 17, 2021 Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock increased by 25.72% to $2.59 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is... Via Benzinga Stocks That Hit 52-Week Lows On Tuesday August 17, 2021 Tuesday morning, 282 companies set new 52-week lows. Key Facts: Alibaba Group Holding (NYSE:BABA) was the biggest company by market cap to set a new 52-week low.... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.